Previous close | 4.0110 |
Open | 4.1600 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 4.0900 - 4.4500 |
52-week range | 3.9000 - 22.7000 |
Volume | |
Avg. volume | 2,732 |
Market cap | 24.486M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -16.0000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its full-year financial results for the year ended December 31, 2023, and provided a business update.
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it had had received a staff determination letter (the "Letter") on April 30, 2024 from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, due to the Company's non-compliance with t
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that the company's Chief Science Officer, Dr. Tamar Ben-Yedidia, and the University Medical Center Göttingen's Director, Department of Dermatology, Venereology & Allergology, Prof. Michael Schön, will be presenting together at the upcoming 5th Dermatology